Anest. intenziv. Med. 2011;22(4):197-199

Nová farmaka - jak s nimi?Editorial

Cvachovec Karel

Published: August 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cvachovec K. Nová farmaka - jak s nimi? Anest. intenziv. Med. 2011;22(4):197-199.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Munos, B. Lessons from 60 years of pharmaceutical innovation. Nature reviews, 2009, 8, p. 959-968. Go to original source... Go to PubMed...
    2. Abrishami, A., Ho, J., Wong, J., Yin, L., Chung, F. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database Syst Rev., 2009, Oct 7, 4, CD007362. Go to original source... Go to PubMed...
    3. Hawkins, J. L., Chang, J., Palmer et al. Anesthesia-related maternal mortality in the United States 1979-2002. Obst. Gyn., 2011,117, 1, p. 69-74. Go to original source... Go to PubMed...
    4. Li, G., Warner, M., Lang, B. H., Juany, L., Sun, L.S. Epidemiology of anesthesia-related mortality in the United States, 1999-2005. Anesthesiology, 2009, 110, p. 759-65. Go to original source... Go to PubMed...
    5. Lienhart, A., Auroy, Y., Péquignot, F., Benhamou, D. et al. Survey of anesthesia-related mortality in France. Anestesiology, 2006, 105, p. 1087-1097. Go to original source... Go to PubMed...
    6. Černý, V., Adamus, M., Cvachovec, K., Ševčík, P., Herold, I. Anestezie v České republice 2010 - jednodenní prospektivní observační dotazníková studie. Anest. intenziv. Med., 2011, 22, 1, s. 5-12.
    7. Murphy, G. S., Brull, S. J. Residual Neuromuscular Block: Lessons Unlearned. Part I: Definitions, Incidence, and Adverse Physiologic Effects of Residual Neuromuscular Block. Anesth. Analg., 2010, 111, 1, p. 120-128. Go to original source... Go to PubMed...
    8. Khuri, S. F., Henderson, W. G., DePalma, R. G. Et al. Determinants of long-term Survival after Major Surgery and the Adverse Effect of Postoperative Complications. Ann. Surg., 2005, 242, 3, p. 326-343. Go to original source...
    9. Dimick, J. B., Chen, S. L., Taheri, P. A. et al. Hospital costs associated with surgical complications: a report from the private-sector. National Surgical Quality Improvement Program. J. Am. Coll. Surg., 2004, 199, p. 531-537. Go to original source... Go to PubMed...
    10. Smetana, G. W. Postoperative pulmonary complications: an update on risk assessment and reduction. Cleve Clin. J. Med., 2009, 76, Suppl. 4, p. S60-65. Go to original source... Go to PubMed...
    11. Paton, F., Paulden, M., Chambers, D. et al. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. Brit. J. Anaesth., 2010, 105, 5, p. 558-567. Go to original source... Go to PubMed...
    12. Mellin-Olsen, J., Staender, S., Whitaker, D., Smith, A. F. The Helsinky Declaration on Patient Safety in Anaesthesiology. Eur. J. Anaesthesiol., 2010, 27, p. 592-597. Go to original source... Go to PubMed...
    13. Groudine, S. B., Soto, R., Lien, C., Drover, D., Roberts, K. A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth. Analg., 2007, 104, 3, p. 555-562. Go to original source... Go to PubMed...

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.